AnaptysBio reports positive data

AnaptysBio Inc. (Nasdaq: ANAB) reported positive proof-of-concept data from an ongoing Phase 2a clinical trial of ANB020 to treat moderate to severe atopic dermatitis. Shares of the biotechnology firm more than doubled by leaping $35.41 to close at $70.41.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.